AstraZeneca reports Q1 net loss of Rs 12 cr, total income at Rs 396 cr

Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing

AstraZeneca
The drug maker had reported a net profit of Rs 54 crore in the April-June quarter of last fiscal.
Press Trust of India New Delhi
1 min read Last Updated : Aug 08 2024 | 7:49 PM IST

AstraZeneca Pharma India on Thursday said its net loss stood at Rs 12 crore for the first quarter ended June 30, 2024.

The drug maker had reported a net profit of Rs 54 crore in the April-June quarter of last fiscal.

Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing.

"We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programmes focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers and non-government organisations," AstraZeneca India Country President and Managing Director Sanjeev Panchal said.

Shares of AstraZeneca Pharma on Thursday ended 6.77 per cent lower at Rs 6,613.40 apiece on the BSE.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :AstraZenecaPharma sectorQ1 results

First Published: Aug 08 2024 | 7:49 PM IST

Next Story